INTENSITY THERAPEUTICS, INC.
INTS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INTS
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing intratumorally administered cancer therapies, with its lead candidate INT230-6 currently in Phase 3 trials for soft tissue sarcoma and other solid tumors.
Key risk: Cash runway limited
BioSniper Score
Based on 5 of 6 signals
Market Cap
$13.9M
Cash Runway
12.9 moLead Asset
int230-6 (Phase 3)Next Catalyst
Phase3_Topline · Dec 1, 2028Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial · 1 catalyst for INTENSITY THERAPEUTICS, INC..
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing intratumorally administered cancer therapies, with its lead candidate INT230-6 currently in Phase 3 trials for soft tissue sarcoma and other solid tumors.
- Lead product candidate INT230-6 is being evaluated in the Phase 3 INVINCIBLE-4 study for soft tissue sarcoma; enrollment resumed in Q2 2026 after a protocol amendment, with completion targeted by end of 2027 [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company reported cash and cash equivalents of approximately $9.5 million [sec_mda · as of 2026-08-11].
- The company has incurred net losses since inception and expects to continue incurring losses; accumulated deficit was approximately $78.4 million as of December 31, 2025 [sec_mda · as of 2026-03-27].
- Research has been published in peer-reviewed journals such as OncoImmunology and eBioMedicine, and presented at major conferences including ASCO, SITC, and CTOS [sec_mda · as of 2026-08-11].
- The company has not generated any revenue from product sales and has funded operations through issuances of common stock, preferred stock, and convertible notes [sec_mda · as of 2026-08-11].
What works
- INT230-6 has shown a 44% reduction in grade 3 adverse events and fewer immune-related adverse events when added prior to immunochemotherapy in a clinical cohort [sec_mda · as of 2026-08-11].
- The company has successfully developed Phase 3 quality analytical methods and manufactured a large-scale batch of INT230-6, with an agreed CMC plan with the FDA for registration [sec_mda · as of 2026-03-27].
- Research has been peer-reviewed and published in high-impact journals, including a paper co-authored with the NCI [sec_mda · as of 2026-08-11].
What to weigh
- The company has incurred net losses since inception and expects to continue incurring significant expenses; as of June 30, 2026, cash and equivalents were only $9.5 million, which may require additional funding to complete ongoing trials [sec_mda · as of 2026-08-11].
- There is substantial doubt about the company's ability to continue as a going concern, as stated in its financial reports [sec_mda · as of 2026-03-27].
- The company has not generated any revenue from product sales and relies entirely on external financing to fund operations [sec_mda · as of 2026-08-11].
- If sufficient additional funding is not obtained, the company may have to delay completion of the INVINCIBLE-4 study [sec_mda · as of 2026-03-27].
From the filings
Quoted directly from source documents.
Lead candidate INT230-6 is in Phase 3 for soft tissue sarcoma; enrollment resumed in Q2 2026.
“In March 2026, a protocol amendment was approved by the Swissmedic and the Swiss Ethics Committee to use a lower drug volume per tumor volume ratio and a single injection of INT230-6, and patient enrollment was resumed in the second quarter of 2026.”
SEC MD&A · August 11, 2026
Cash position as of June 30, 2026.
“As of June 30, 2026, we had approximately $9.5 million of cash and cash equivalents.”
SEC MD&A · August 11, 2026
Accumulated deficit as of December 31, 2025.
“As of December 31, 2025 and 2024, we had an accumulated deficit of approximately $78.4 million and $66.8 million, respectively.”
SEC MD&A · March 27, 2026
Going concern uncertainty.
“Our financial statements have been prepared assuming we will continue as a going concern. We have incurred losses from operations and negative cash flows from operations that raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · March 27, 2026
Catalyst timeline
- 2028-12-01 · Phase 3 Topline — Topline data readout from the Phase 3 INVINCIBLE-4 study assessing INT230-6 in soft tissue sarcoma.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Only $9.5M cash as of June 30, 2026; may need additional funding to complete Phase 3 trial [sec_mda · as of 2026-08-11].
- Going concern doubt — Substantial doubt about ability to continue as a going concern due to recurring losses [sec_mda · as of 2026-03-27].
- No product revenue — No revenue from product sales; operations funded solely by equity/debt issuances [sec_mda · as of 2026-08-11].
- Clinical trial delay risk — If funding insufficient, completion of INVINCIBLE-4 study may be delayed [sec_mda · as of 2026-03-27].
What to watch
- Enrollment progress and topline data from the Phase 3 INVINCIBLE-4 study for INT230-6 in soft tissue sarcoma [sec_mda · as of 2026-08-11].
- Ability to secure additional financing to fund operations and clinical trials [sec_mda · as of 2026-08-11].
- Regulatory milestones, including FDA interactions and CMC plan execution for INT230-6 [sec_mda · as of 2026-03-27].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run INTENSITY THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INTENSITY THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
12.9 months
D/E 0.25 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~824d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$846K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 33,682 | $198K |
| geode capital management, llc | 26,019 | $153K |
| sapient capital llc | 26,006 | $153K |
| nano cap new millennium growth fund l p | 25,000 | $147K |
| rothschild wealth llc | 23,294 | $137K |
| vanguard fiduciary trust co | 9,121 | $54K |
| osaic holdings, inc. | 200 | $1K |
| wells fargo & company/mn | 200 | $1K |
| ubs group ag | 192 | $1K |
| tower research capital llc (trc) | 67 | $394 |
Showing top 10 of 11 institutional holders of INTENSITY THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 2.5%
- Days to cover
- 2.2
- Shares short
- 61,082
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INTS short interestGovernance
Frequently asked questions
What is the AI investment thesis for INTENSITY THERAPEUTICS, INC.?
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing intratumorally administered cancer therapies, with its lead candidate INT230-6 currently in Phase 3 trials for soft tissue sarcoma and other solid tumors.
What is INTENSITY THERAPEUTICS, INC.'s lead drug candidate?
INTENSITY THERAPEUTICS, INC.'s most advanced tracked candidate is int230-6 (Phase 3) for Sarcoma,Soft Tissue.
What is INTENSITY THERAPEUTICS, INC.'s next catalyst?
INTENSITY THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Adminis" — expected December 1, 2028.
Who is the CEO of INTENSITY THERAPEUTICS, INC.?
Mr. Lewis H. Bender M.A., M.B.A., M.S. is the chief executive officer of INTENSITY THERAPEUTICS, INC. (INTS).
Where is INTENSITY THERAPEUTICS, INC. headquartered?
INTENSITY THERAPEUTICS, INC. (INTS) is headquartered in Shelton, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.